Threshold Pharmaceuticals Announces Presentation and Webcast at the Cowen and Company 36th Annual Health Care Conference
March 09 2016 - 6:46PM
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that
Barry Selick, Ph.D., Threshold’s Chief Executive Officer, will
present a company overview at the Cowen and Company 36th Annual
Health Care Conference on March 8, 2016, at 9:20 a.m. Eastern Time.
A live webcast of the presentation will be
available under "Webcasts" in the Investors section of
www.thresholdpharm.com. A replay of the presentation will be
archived on the site for 30 days.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a biotechnology company focused
on the development of drugs targeting tumor hypoxia, the low oxygen
condition found in the microenvironments of most solid tumors, as
well as the bone marrows of some patients with hematologic
malignancies. This approach offers broad potential to treat a
variety of cancers. By selectively targeting tumor cells, we have a
pipeline of drugs that hold promise to be more effective and less
toxic to healthy tissues than conventional anticancer drugs. For
additional information, please visit our website
(www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the
statements in this press release are forward-looking statements,
including statements regarding the potential therapeutic uses and
benefits of its drug candidates. These statements involve risks and
uncertainties that can cause actual results to differ materially
from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to: Threshold’s
need for and the availability of resources to develop its drug
candidates and to support Threshold's operations including the
expense required to conduct clinical trials and analyze data;
issues arising in the regulatory or manufacturing process and the
results of such clinical trials (including product safety issues
and efficacy results). Further information regarding these and
other risks is included under the heading "Risk Factors" in
Threshold's Quarterly Report on Form 10-Q, which has been filed
with the Securities and Exchange Commission on November 2, 2015 and
is available from the SEC's website (www.sec.gov) and on our
website (www.thresholdpharm.com) under the heading "Investors." We
undertake no duty to update any forward-looking statement made in
this news release.
Contact
Mark Hopkins, Ph.D., J.D.
Vice President of Intellectual Property and Assistant General Counsel
Phone: 650-474-8213
E-mail: mhopkins@thresholdpharm.com
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Apr 2024 to May 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From May 2023 to May 2024